Is there a one-size-fits-all approach to qualification and validation?
Not every machine needs to be qualified in exactly the same way.
Dr. Dave Seaward : 28 February 2022
In this third instalment to our cell and gene blog series, author Dave Seaward explains where most ATMP technology is being delivered as well as providing insight into why.
Click here to gain an understanding of why investors believe significant returns will be made from these technologies.
Not every machine needs to be qualified in exactly the same way.
Around 1,000 people are diagnosed with cancer every day in the UK. Fortunately, outcomes continue to improve, with around half of those diagnosed...
In this latest blog, James Lau, one of 3P’s Project Engineers, tells us all about barrier systems across a range of areas. Specifically taking a...